Why does no GLP-1 dose fit someone between the trial cohorts?

Tirzepatide and semaglutide doses jump in big steps. Anyone whose tolerance sits between 5 mg and 7.5 mg cycles through nausea, plateaus, and unauthorized self-titration. Telehealth clinicians won't deviate from the label.

Category: HealthTech · Trend: AI · Opportunity score: 8.0 / 10

What is the “Why does no GLP-1 dose fit someone between the trial cohorts?” problem in 2026?

Tirzepatide and semaglutide doses jump in big steps. Anyone whose tolerance sits between 5 mg and 7.5 mg cycles through nausea, plateaus, and unauthorized self-titration. Telehealth clinicians won't deviate from the label.

Who has this problem?

GLP-1 patients on Zepbound, Wegovy, Mounjaro, Ozempic who can't tolerate the next labelled dose.

Evidence this problem is real

“5 mg works for two weeks then plateaus. 7.5 mg puts me in bed for three days. My telehealth doc says that's not a thing. The subreddit has 4,000 of us doing micro-doses with kitchen scales.”

Sourced from r/Mounjaro, r/Zepbound, r/Ozempic dose-titration megathreads with 10K+ comments through 2025 and 2026.

Existing players in this space

  • Telehealth clinics (Ro, Hims, Sequence) — Stick to label, won't customise between doses
  • Compounded pharmacies — Mostly delisted post-FDA shortage end, legally squeezed
  • Reddit DIY titration spreadsheets — Best resource patients have today, unsupervised

What existing players are missing

An evidence-curated micro-titration coach: log side-effect patterns, weight, food intake, suggest the dose the patient's GP can actually prescribe under shared-decision-making, with the citations attached. Connects to a real prescriber for the off-label step, not a vending machine.

How Real Problem AI scores this opportunity

Aggregate score: 8.0 / 10. Four-axis rubric:

  • Problem severity: 8 / 10
  • AI feasibility today: 7 / 10
  • Market signal: 9 / 10
  • Competition gap: 8 / 10

How to build a solution: stack hints

  • Symptom and dose journal with side-effect taxonomy
  • Curated trial and registry data, citation-first responses
  • Shared-decision-making PDF the patient walks into their GP's office with
  • Prescriber network for off-label dosing where allowed

Related HealthTech problems on Real Problem AI